Osteoporosis is a highly prevalent condition characterized by decreases in bone mass and
microarchitectural alterations. Bone fractures, especially of the hip and vertebrae, are the …

Osteoporosis is the leading cause of fractures in the population older than 50 years. This
silent disease affects primarily postmenopausal women and the elderly, and the morbidity …

Bone biology is physiologically complex and intimately linked to calcium homeostasis. The
literature provides a wealth of qualitative and/or quantitative descriptions of cellular …

Data on treatment of glucocorticoid‐induced osteoporosis (GIO) in men are scarce. We
performed a randomized, open‐label trial in men who have taken glucocorticoids (GC) for≥ …

Introduction: EUROFORS was a 2-yr prospective, randomized trial of postmenopausal
women with established osteoporosis, designed to investigate various sequential treatments …

Glucocorticoids (GC) are an important risk factor for bone fragility in children with serious
illnesses, largely due to their direct adverse effects on skeletal metabolism. To better …

Objective To assess the efficacy and safety of 18 months of subcutaneous abaloparatide
(ABL-SC) or placebo (PBO) followed by 6 months of alendronate (ALN)(preplanned interim …

Osteoporosis is the leading cause of fractures in the population older than 50 years. This
silent disease affects primarily postmenopausal women and the elderly, and the morbidity …

Bisphosphonates are widely used for the treatment of bone diseases associated with
increased osteoclastic bone resorption. Bisphosphonates are known to inhibit biochemical …

When teriparatide and denosumab are discontinued, bone mineral density (BMD) abruptly
decreases. To compare rates of bone loss in postmenopausal women who discontinue …